The pharmaceutical bets of Jefferies are the laboratories of Divi and 3 Smallcaps, with a maximum of 30% advantage. This is why

The CRDMO sector of India will benefit from the steel wind that can stimulate growth in its growth for the next 3-5 years, the global brokerage Jefferies said in a note because it opted for four shares from the sector for profit up to 30%. After 50 investor meetings where American brokerage, the recommendations were told important factors in the midst of worries about the appreciation and a volatile profit profile of the companies.

Shares to buy

1) Divis Labs: These Largecap shares remain a top deployment in the sector, given its track record and a good ownership share for domestic investors. The target has been set at RS 7,150, which reflects an advantage of 19%. While investors agreed on the growth from the middle to the long term of Divi, the worries remain if all growth is already priced and the consolidated estimates are too high to satisfy.

2) Lifesciences from CoHance: This SmallCap share is recommended for a target of RS 1,150, which indicates an advantage of 17%. Despite a fall of 17% 1 year, there is a considerable interest in the name, says Jefferies. Investors bet on a strong pipeline and healthy growth visibility for the production of ADC -Payload and would like to know when organic growth is reflected. It is a multibagger with a return of 105% for a period of 3 years.

3) Sai Life Sciences: The brokerage recommends a buy for this share for a target of RS 1,100, an advantage of 27%. A good series of results has brought faith in the name. The visibility of the project that can stimulate growth has improved considerably in the past quarters, Jefferies said in a note. But easy return and most of the re-rating is behind, it said.

4) Pyramal Pharma: This is still a smallcap bet with a 30% advantage. The target has been set at RS 260. The share has fallen during the period of 1 year. Jefferies sees significant investor interest as a result of valuation discount versus colleagues.

Also read: LIC shares fall 15% in a year, more than 70% of the portfolio shares fall to 70%

Red flag

Laurus Good: A Midcap Multibagger shares with a return of 5 years of 256%. While investors agreed on a robust CRDMO and prospects in the short term, lack of guidance creates uncertainty. Investors are wary of the increasing risks for his ARV activities, since new therapy is planned for the LMIC ARV segment, said Jefferies Note, which showed that different investors expressed concern about high valuation. It has an ‘underperform’ rating on the counter.(Disclaimer: recommendations, suggestions, views and opinions of the experts are their own. These do not represent the views of economic times)